Table 1. Primary resistance and PFS in EGFR-mutant nonsmall cell lung cancer patients treated with EGFR TKIs as first-line therapy in major phase III trials.

First author [ref.]	EGFR mutation type	Patients n	TKI	Progressive disease as best overall response %	Progressive or stable disease as best overall response %	Median PFS months
Mok [5]	Common/rare	132	Gefitinib	8	28	9.5
Mistudomi [6]	Common	86	Gefitinib	7	38	9.2
Maemondo [7]	Common/rare	228	Gefitinib	10	25	10.8
Rosell [8]	Common	86	Erlotinib	7	28	9.7
Zhou [9]	Common	83	Erlotinib	4#	20¶	13.1
Sequist [10]	Common/rare	230	Afatinib	10#	44¶	11.1
Wu [11]	Common/rare	242	Afatinib	4	25	11.0

PFS: progression-free survival; EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor. ^#: calculated as percentage of patients who did not achieve disease control; ^¶: calculated as percentage of patients who did not achieve an objective response.